4min chapter

Breakpoints cover image

#68 – IDWeek 2022 Recap: Late Breaking Trials and Pipeline Antibacterials

Breakpoints

CHAPTER

Cepheum Tannibor Bactam

Cepheum tannibor bactam, which was developed by Venetatorex. This agent is currently in phase 2 studies looking again at that treatment refactory MAC disease of the lung. It's a bicyclic boronate beta lactamase inhibitor. And so what does that mean? It means it inhibits serine and metallobatal actamases. So they're going to pursue NDA submission 2023 and we'll also start a HAP VAP trial for that.

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode